← Browse by Condition
Medical Condition

tace

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT05920863 Phase 2
Recruiting

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Enrollment
35 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
View Trial →